IP Library Granted Patent US 11,123,355
Granted Patent B2
US 11,123,355 · App. 16/471,304 · Granted Sep 21, 2021

Antiviral benzyl-amine phosphodiamide compounds

Inventors: Manuel de Lera Ruiz (Perkasie, PA); Timothy J. Hartingh (Richlandtown, PA); Izzat Raheem (Doylestown, PA); John Schreier (Harleysville, PA); Jean-Laurent Paparin (Vendemian, FR)
Assignees: Idenix Pharmaceuticals LLC; Merck Sharp & Dohme Corp.
A61K31/675A61K31/496A61K31/536A61P31/18C07D473/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,123,355
App. No.
16/471,304
Granted
Sep 21, 2021
Kind
B2
Abstract

Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

Claims (144)

1. A compound of structural Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is —C 1-6 alkyl;

R 2 is —C 1-6 alkyl;

or R 1 and R 2 are joined together with the carbon to which they are both attached to form spiro-C 3-6 cycloalkyl;

R 3 is:

(a) —C 1-10 alkyl unsubstituted or substituted with one, two or three of fluoro, chloro, bromo, —CN, —CF 3 , —OR 5 , —SR c , —NR 6 R 7 , —C 3-6 cycloalkyl or spiro-C 3-6 cycloalkyl,

(b) —CH 2 -phenyl unsubstituted or substituted with one, two or three of fluoro, chloro, bromo, —OR 4 , —SR, —NR 6 R 7 or —C 1-3 alkyl,

(c) —C 3-8 cycloalkyl unsubstituted or substituted with one, two or three of fluoro, chloro, bromo, —OR 4 , —SR, —NR 6 R 7 or —C 1-3 alkyl,

(d) aryl unsubstituted or substituted with one, two or three of fluoro, chloro, bromo, —OR 4 ,

—SR, —NR 6 R 7 or —C 1-3 alkyl,

(e) —C 1-5 alkyl-X—C 1-5 alkyl wherein X is O, S or NH,

(f) heteroaryl unsubstituted or substituted with one, two or three of fluoro, chloro, bromo, —OR 4 , —SR, —NR 6 R 7 or —C 1-3 alkyl, or

(g) a heterocyclic ring unsubstituted or substituted with one, two or three of fluoro, chloro, bromo, —OR 4 , —SR, —NR 6 R 7 or —C 1-3 alkyl;

R is —H, —CF 3 , —C 1-3 alkyl or —C 3-6 cycloalkyl;

R c is —H, —CF 3 or —C 3-6 cycloalkyl;

R 4 is —H, —CF 3 , —C 1-3 alkyl or —C 3-6 cycloalkyl;

R 5 is —H, —CF 3 or C 3-6 cycloalkyl;

R 6 is —H, —C 1-3 alkyl or —C 3-6 cycloalkyl;

R 7 is —H, —C 1-3 alkyl or —C 3-6 cycloalkyl;

R 8 is —H or —C 1-3 alkyl;

R 9 is —H, —C 1-6 alkyl or —C 1-6 alkyl substituted with 1 to 3 of F;

R 10 is —H, —C 1-6 alkyl or —C 1-6 alkyl substituted with 1 to 3 of F;

or R 9 and R 10 are joined together with the carbon to which they are both attached to form spiro-C 3-6 cycloalkyl;

R a is halo, —CN, —C 1-6 alkyl, —C 1-6 alkyl substituted with 1 to 3 of F, —OC 1-6 alkyl or —OC 1-6 alkyl substituted with 1 to 3 of F; and

R b is —H, halo, —CN, —C 1-6 alkyl, —C 1-6 alkyl substituted with 1 to 3 of F, —OC 1-6 alkyl or —OC 1-6 alkyl substituted with 1 to 3 of F.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 1 and R 2 are each independently selected from —C 1-4 alkyl, or R 1 and R 2 are joined together with the carbon to which they are both attached to form spiro-C 3-6 cycloalkyl.

3. The compound of claim 2 or a pharmaceutically acceptable salt thereof wherein R 1 and R 2 are the same moiety selected from —C 1-4 alkyl, or R 1 and R 2 are joined together with the carbon to which they are both attached to form spiro-C 3-6 cycloalkyl.

4. The compound of claim 2 or a pharmaceutically acceptable salt thereof wherein R 9 and R 10 are each independently —H, —C 1-3 alkyl or —C 1-3 alkyl substituted with 1 to 3 of F, or R 9 and R 10 are joined together with the carbon to which they are both attached to form spiro-C 3-6 cycloalkyl.

5. The compound of claim 4 or a pharmaceutically acceptable salt thereof wherein R 9 and R 10 are each independently —H, —CH 3 or —CF 3 , or R 9 and R 10 are joined together with the carbon to which they are both attached to form spiro-C 3-6 cycloalkyl.

6. The compound of claim 5 or a pharmaceutically acceptable salt thereof wherein R 9 and R 10 are the same moiety selected from —C 1-6 alkyl.

7. The compound of claim 2 or a pharmaceutically acceptable salt thereof wherein R a is halo, —CN, —C 1-3 alkyl, —C 1-3 alkyl substituted with 1 to 3 of F,

—OC 1-3 alkyl or —OC 1-3 alkyl substituted with 1 to 3 of F.

8. The compound of claim 7 or a pharmaceutically acceptable salt thereof wherein R b is —H, halo, —CN, —C 1-3 alkyl, —C 1-3 alkyl substituted with 1 to 3 of F, —OC 1-3 alkyl or —OC 1-3 alkyl substituted with 1 to 3 of F.

9. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 3 is:

(a) —C 1-8 alkyl, —CH 2 CH 2 OH, —CH 2 CH 2 CH 2 OH, —CH 2 CH 2 SH, —CH 2 CH 2 CH 2 SH, —CH 2 CH 2 NH 2 , —CH 2 CH 2 CH 2 NH 2 ,

(b) —CH 2 -phenyl, unsubstituted or substituted with one, two or three substituents independently selected from fluoro, chloro, bromo, —OR 4 , —SR, —NR 6 R 7 or —C 1-3 alkyl,

(c) —C 3-6 cycloalkyl, unsubstituted or substituted with one, two or three substituents independently selected from fluoro, chloro, bromo, —OR 4 , —SR —NR 6 R 7 or —C 1-3 alkyl,

(d) phenyl or naphthyl, each unsubstituted or substituted with one, two or three substituents independently selected from fluoro, chloro, bromo, —OR 4 , —NR 6 R 7 or

—C 1-3 alkyl,

(e) —CH 2 CH 2 OCH 3 , —CH 2 CH 2 OCH 2 CH 3 , —CH 2 CH 2 CH 2 OCH 3 , —CH 2 CH 2 CH 2 OCH 2 CH 3 ,

—CH 2 CH 2 SCH 3 , —CH 2 CH 2 SCH 2 CH 3 , —CH 2 CH 2 CH 2 SCH 3 , —CH 2 CH 2 CH 2 SCH 2 CH 3

—CH 2 CH 2 NHCH 3 , —CH 2 CH 2 NHCH 2 CH 3 , —CH 2 CH 2 CH 2 NHCH 3 , or

—CH 2 CH 2 CH 2 NHCH 2 CH 3 ;

(f) pyridyl, unsubstituted or substituted with one, two or three substituents independently selected from fluoro, chloro, bromo, OR 4 , —SR, —NR 6 R 7 or —C 1-3 alkyl, or

(g) piperidinyl, pyrrolidinyl, tetrahydrofuranyl, or tetrahydropyranyl, each unsubstituted or substituted with one, two or three substituents independently selected from fluoro, chloro, bromo, OR 4 , —SR, —NR 6 R 7 or —C 1-3 alkyl.

10. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 3 is —C i-8 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or —C 1-3 alkyl-O—C 1-3 alkyl.

11. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 3 is —C 1-6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

12. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein:

R 1 and R 2 are both methyl, ethyl, propyl or i-propyl;

R 3 is —C 1-6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

R 8 is —H or —C 1-3 alkyl;

R 9 is —H, —C 1-3 alkyl or —C 1-3 alkyl substituted with 1 to 3 of F;

R 10 is —H, —C 1-3 alkyl or —C 1-3 alkyl substituted with 1 to 3 of F;

or R 9 and R 10 are joined together with the carbon to which they are both attached to form spiro-C 3-6 cycloalkyl;

R a is halo, —CN, —C 1-3 alkyl, —C 1-3 alkyl substituted with 1 to 3 of F, —OC 1-3 alkyl or —OC 1-3 alkyl substituted with 1 to 3 of F; and

Rb is —H, halo, —CN, —C 1-3 alkyl, —C 1-3 alkyl substituted with 1 to 3 of F, —OC 1-3 alkyl or —OC 1-3 alkyl substituted with 1 to 3 of F.

13. The compound of claim 1 that is

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-chlorophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-chlorophenyl)ethyl)(methyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-chlorophenyl)ethyl)(methyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-2,2,2-trifluoro-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-2,2,2-trifluoro-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-3-(6-amino-9H-purin-9-yl)-1,1,1-trifluoropropan-2-yl)oxy)methyl)(((R)-2,2,2-trifluoro-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-3-(6-amino-9H-purin-9-yl)-1,1,1-trifluoropropan-2-yl)oxy)methyl)(((R)-2,2,2-trifluoro-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((4-isopropylbenzyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((4-isopropylbenzyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((4-cyanobenzyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((4-cyanobenzyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((4-(trifluoromethoxy)benzyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((4-(trifluoromethoxy)benzyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((3-fluorobenzyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((3-fluorobenzyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(3-fluorophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(3-fluorophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(3-fluorophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(3-fluorophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(4-(trifluoromethyl)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(4-(trifluoromethyl)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-(trifluoromethyl)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-(trifluoromethyl)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(4-chlorophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(4-chlorophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(4-methoxyphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(4-methoxyphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-methoxyphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-methoxyphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(p-tolyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(p-tolyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(2-methoxyphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(2-methoxyphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(p-tolyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(p-tolyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(2-methoxyphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(2-methoxyphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(2-methyl-4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(2-methyl-4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-2,2,2-trifluoro-1-(3-fluorophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-2,2,2-trifluoro-1-(3-fluorophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-cyanophenyl)-2,2,2-trifluoroethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-cyanophenyl)-2,2,2-trifluoroethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(4-cyanophenyl)-2,2,2-trifluoroethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(4-cyanophenyl)-2,2,2-trifluoroethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-2,2,2-trifluoro-1-(3-methoxyphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-2,2,2-trifluoro-1-(3-methoxyphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-2,2,2-trifluoro-1-(p-tolyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-2,2,2-trifluoro-1-(p-tolyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-2,2,2-trifluoro-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-2,2,2-trifluoro-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-2,2,2-trifluoro-1-(3-methoxyphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-2,2,2-trifluoro-1-(3-methoxyphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-chloro-2-methylphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl) (((R)-1-(4-chloro-2-methylphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(4-chloro-2-methylphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((S)-1-(4-chloro-2-methylphenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-cyanophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-cyanophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((4-isopropylbenzyl)(methyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((4-isopropylbenzyl)(methyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(methyl((R)-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

propyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(methyl((R)-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

isopropyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-(trifluoromethoxy)phenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

isopropyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-chlorophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-chlorophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

isopropyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((2-(4-chlorophenyl)propan-2-yl)amino)phosphoryl)amino)-2-methylpropanoate;

isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((2-(4-chlorophenyl)propan-2-yl)amino)phosphoryl)amino)-2-methylpropanoate;

isopropyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((1-(4-chlorophenyl)cyclopropyl)amino)phosphoryl)amino)-2-methylpropanoate; or

isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((1-(4-chlorophenyl)cyclopropyl)amino)phosphoryl)amino)-2-methylpropanoate;

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 13 , selected from:

isopropyl 2-(((R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((R)-1-(4-chlorophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate; or

isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl) (((R)-1-(4-chlorophenyl)ethyl)amino)phosphoryl)amino)-2-methylpropanoate;

or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition of claim 15 further comprising an effective amount of one or more additional HIV antiviral agent selected from HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors and HIV entry inhibitors.

17. The pharmaceutical composition of claim 15 further comprising an effective amount of one or more additional HIV antiviral agent selected from:

abacavir, abacavir sulfate, abacavir+lamivudine, abacavir+lamivudine+zidovudine, amprenavir, atazanavir, atazanavir sulfate, AZT, capravirine, darunavir, dideoxycytidine, dideoxyinosine, delavirdine, delavirdine mesylate, dolutegravir, doravirine, efavirenz, 4′-ethynyl-2-fluoro-2′-deoxyadenosine, elvitegravir, emtricitabine, emivirine, enfuvirtide, etravirine, fosamprenavir calcium, indinavir, indinavir sulfate, lamivudine, lamivudine+zidovudine, lopinavir, lopinavir+ritonavir, maraviroc, nelfinavir, nelfinavir mesylate, nevirapine, PPL-100, raltegravir, rilpivirine, ritonavir, saquinavir, saquinavir mesylate, stavudine, tipranavir, or vicriviroc.

18. A method for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

19. The method of claim 18 further comprising administering to the subject an effective amount of one or more additional HIV antiviral agent selected from HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors and HIV entry inhibitors.

20. The method of claim 18 further comprising administering to the subject an effective amount of one or more additional HIV antiviral agent selected from:

abacavir, abacavir sulfate, abacavir+lamivudine, abacavir+lamivudine+zidovudine, amprenavir, atazanavir, atazanavir sulfate, AZT, capravirine, darunavir, dideoxycytidine, dideoxyinosine, delavirdine, delavirdine mesylate, dolutegravir, doravirine, efavirenz, ′-ethynyl-2-fluoro-2′-deoxyadenosine, elvitegravir, emtricitabine, emivirine, enfuvirtide, etravirine, fosamprenavir calcium, indinavir, indinavir sulfate, lamivudine, lamivudine+zidovudine, lopinavir, lopinavir+ritonavir, maraviroc, nelfinavir, nelfinavir mesylate, nevirapine, PPL-100, raltegravir, rilpivirine, ritonavir, saquinavir, saquinavir mesylate, stavudine, tipranavir, or vicriviroc.

Assignments (3)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2019
From: PAPARIN, JEAN-LAURENT
To: IDENIX PHARMACEUTICALS LLC.
Reel/Frame 049521/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2019
From: DE LERA RUIZ, MANUEL; HARTINGH, TIMOTHY J.; RAHEEM, IZZAT; SCHREIER, JOHN
To: MERCK SHARP & DOHME CORP.
Reel/Frame 049521/0953 →